一种新型非侵入性检测可在血尿患者尿沉渣中检出膀胱癌——ADXBLADDER 的前瞻性多中心性能评估
该前瞻性多中心盲法研究纳入 856 例血尿患者,评估基于 MCM5 抗体的酶联免疫吸附试验 ADXBLADDER 检测膀胱癌的性能,膀胱癌患病率为 8.6%。ADXBLADDER 总体敏感性为 73.0%,总体阴性预测值为 96.4%;在肌层浸润性膀胱癌中敏感性和阴性预测值均为 100%。在 173 例有细胞学数据的患者中,ADXBLADDER 检出 16/18 例癌症,而细胞学仅 4/18 例阳性。
要点
- ADXBLADDER 在血尿患者中检出膀胱癌的总体敏感性为 73.0%,总体阴性预测值为 96.4%。
- 肌层浸润性膀胱癌中 ADXBLADDER 的敏感性和阴性预测值均为 100%。
- 在 173 例有细胞学数据的患者中,ADXBLADDER 检出 16/18 例癌症,细胞学仅 4/18 例阳性。
核心结论
- 这种新型 ADXBLADDER 尿液检测可帮助检出膀胱癌,并可替代当前标准的尿液检测。
研究设计与样本
- 前瞻性、盲法、多中心研究,纳入 7 个中心共 856 例血尿患者,评估基于 MCM5 抗体的酶联免疫吸附试验 ADXBLADDER 检测膀胱癌的性能。
主要发现
- 膀胱癌患病率为 8.6%。
- ADXBLADDER 在 74 例癌症中检出 54 例,总体敏感性为 73.0%,总体阴性预测值为 96.4%。
- 肌层浸润性膀胱癌中 ADXBLADDER 的敏感性和阴性预测值均为 100%。
- 非 pTa(pT1 及以上)肿瘤分析中,ADXBLADDER 的敏感性为 97%,阴性预测值为 99.8%。
- 173 例有匹配细胞学数据的患者中,18 例膀胱癌阳性,ADXBLADDER 检出 16/18 例,细胞学仅 4/18 例阳性。
临床怎么用
- 作者认为 ADXBLADDER 尿液检测可帮助检出膀胱癌,并可替代当前标准的尿液检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bladder cancer is the sixth most commonly diagnosed cancer in the European Union. Here, we evaluate the performance of a novel, commercially available enzyme-linked immunosorbent assay utilising MCM5 antibodies (ADXBLADDER; Arquer Diagnostics Ltd, Sunderland, UK) for the detection of bladder cancer, in a blinded, prospective study of 856 patients, across seven centres, presenting with haematuria. The results were compared with the patients' clinical data and final diagnosis as defined by the results of the imaging and cystoscopy, with a prevalence of bladder cancer of 8.6%. ADXBLADDER detected bladder tumours in 54/74 cancers, giving overall sensitivity of 73.0% and an overall negative predictive value (NPV) of 96.4%. Sensitivity and NPV of ADXBLADDER were highest in muscle-invasive bladder cancer, both at 100%, and on analysis of non-pTa (pT1 and above) tumours, the sensitivity for detection was 97% with an NPV of 99.8%. A subset of 173 patients had matching cytology data; of these patients, 18 were positive for bladder cancer. ADXBLADDER detected 16/18 of these cancers, whilst cytology was positive in only four of 18, providing evidence that ADXBLADDER may be a more sensitive test for bladder cancer than standard urine cytology. PATIENT SUMMARY: We conducted a large clinical study of a novel, simple urine test (ADXBLADDER), which measures a protein (MCM5) in urine and can be used to detect bladder cancer in patients. We recruited 856 patients and demonstrated that the new urine test can detect bladder cancer with a high degree of accuracy, performing better than the most commonly used urine test-urine cytology. In conclusion, this novel ADXBLADDER urine test can be used to help detect bladder cancers and it can replace the current, standard urine test.
引用
- Dudderidge T, Stockley J, Nabi G, et al. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER. Eur Urol Oncol. 2019. PMID: 31307961. doi:10.1016/j.euo.2019.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。